Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camrelizumab + gemcitabine
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination treatment regimen consisting of camrelizumab and gemcitabine-based chemotherapy. Camrelizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor to restore and enhance T-cell mediated anti-tumor activity. Gemcitabine is a pyrimidine nucleoside analog that functions as a cytotoxic chemotherapy agent by inhibiting DNA synthesis. This specific regimen is being evaluated by the Eye & ENT Hospital of Fudan University as a neoadjuvant and adjuvant therapy in conjunction with endoscopic surgery for patients with recurrent nasopharyngeal carcinoma. The protocol typically involves neoadjuvant cycles of the combination followed by surgical intervention and subsequent maintenance therapy with camrelizumab.
- Brand names
- AiRuiKa
- Other names
- CamrelizumabGemcitabinechemotherapy-Eye & ENT Hospital of Fudan University-nasopharyngeal carcinoma
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)DNA polymerase family
Beyond the preview
Go deeper on camrelizumab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camrelizumab + gemcitabine.